AR041275A1 - Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica - Google Patents
Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceuticaInfo
- Publication number
- AR041275A1 AR041275A1 ARP030103359A ARP030103359A AR041275A1 AR 041275 A1 AR041275 A1 AR 041275A1 AR P030103359 A ARP030103359 A AR P030103359A AR P030103359 A ARP030103359 A AR P030103359A AR 041275 A1 AR041275 A1 AR 041275A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- phenyl
- amino
- heterocyclyl
- Prior art date
Links
- 102000009618 Transforming Growth Factors Human genes 0.000 title abstract 5
- 108010009583 Transforming Growth Factors Proteins 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical class C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 37
- 125000001072 heteroaryl group Chemical group 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- -1 derivatives thereof Chemical class 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 1
- 150000002545 isoxazoles Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41213102P | 2002-09-18 | 2002-09-18 | |
| US48458003P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041275A1 true AR041275A1 (es) | 2005-05-11 |
Family
ID=32033584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103359A AR041275A1 (es) | 2002-09-18 | 2003-09-16 | Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7030125B2 (enExample) |
| EP (1) | EP1542995A1 (enExample) |
| JP (1) | JP2006506443A (enExample) |
| KR (1) | KR20050057441A (enExample) |
| CN (1) | CN1681809A (enExample) |
| AP (1) | AP2005003262A0 (enExample) |
| AR (1) | AR041275A1 (enExample) |
| AU (1) | AU2003263431A1 (enExample) |
| BR (1) | BR0314286A (enExample) |
| CA (1) | CA2499332A1 (enExample) |
| CO (1) | CO5550458A2 (enExample) |
| EA (1) | EA200500286A1 (enExample) |
| EC (1) | ECSP055685A (enExample) |
| HR (1) | HRP20050246A2 (enExample) |
| IS (1) | IS7695A (enExample) |
| MA (1) | MA27444A1 (enExample) |
| MX (1) | MXPA05002378A (enExample) |
| NO (1) | NO20051852L (enExample) |
| OA (1) | OA12925A (enExample) |
| PA (1) | PA8583101A1 (enExample) |
| PE (1) | PE20050076A1 (enExample) |
| PL (1) | PL375973A1 (enExample) |
| TW (1) | TW200410954A (enExample) |
| UY (1) | UY27983A1 (enExample) |
| WO (1) | WO2004026865A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2498047C (en) * | 2002-09-18 | 2009-05-19 | Pfizer Products Inc. | Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
| PL375975A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors |
| EP1542684B1 (en) * | 2002-09-18 | 2009-12-02 | Pfizer Products Inc. | Novel pyrazole compounds as transforming growth factor (tgf) inhibitors |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| WO2006101521A2 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| AU2005286647A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| AR051026A1 (es) | 2004-09-20 | 2006-12-13 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| AU2005286846A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| EP1919882A2 (en) | 2005-02-17 | 2008-05-14 | Synta Pharmaceuticals Corporation | Isoxazole combretastatin derivatives for the treatment of proliferative disorders |
| JP2009513563A (ja) | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
| BRPI0619966A2 (pt) * | 2005-12-16 | 2011-10-25 | Alcon Inc | controle de pressão intra-ocular usando agentes de modulação de alk5 |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| BR112015023261A2 (pt) | 2013-03-14 | 2017-07-18 | Massachusetts Inst Technology | composições e métodos para expansão e cultura de células-tronco epiteliais |
| LT3089971T (lt) | 2014-01-01 | 2020-10-12 | Medivation Technologies Llc | Junginiai ir panaudojimo būdai |
| KR102493376B1 (ko) | 2014-09-03 | 2023-01-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법 |
| EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| JP2019506153A (ja) | 2016-01-08 | 2019-03-07 | マサチューセッツ インスティテュート オブ テクノロジー | 分化した腸内分泌細胞およびインスリン産生細胞の作製 |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| AU2017235461B2 (en) | 2016-03-15 | 2023-02-23 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| CA3048220A1 (en) | 2016-12-30 | 2018-07-05 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
| EP3837351A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| CA3109647A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| CA3124700A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5095272A (enExample) * | 1973-12-24 | 1975-07-29 | ||
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| PL336990A1 (en) | 1997-05-22 | 2000-07-31 | Searle & Co | 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38 |
| CA2288787A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | Pyrazole derivatives as p38 kinase inhibitors |
| ES2187473T3 (es) | 1999-04-09 | 2003-06-16 | Smithkline Beecham Corp | Triarylimidazoles. |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| WO2002040468A1 (en) | 2000-11-16 | 2002-05-23 | Smithkline Beecham Corporation | Compounds |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| JP2004521915A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Ｔｇｆ過剰発現に対するピラゾール誘導体 |
| GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| WO2002062787A1 (en) * | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| GB0102668D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| US6673818B2 (en) * | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| JP2005539000A (ja) | 2002-07-31 | 2005-12-22 | スミスクライン・ビーチャム・コーポレイション | Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体 |
-
2003
- 2003-09-12 MX MXPA05002378A patent/MXPA05002378A/es active IP Right Grant
- 2003-09-12 CA CA002499332A patent/CA2499332A1/en not_active Abandoned
- 2003-09-12 AU AU2003263431A patent/AU2003263431A1/en not_active Abandoned
- 2003-09-12 CN CNA038222043A patent/CN1681809A/zh active Pending
- 2003-09-12 HR HR20050246A patent/HRP20050246A2/hr not_active Application Discontinuation
- 2003-09-12 EP EP03797466A patent/EP1542995A1/en not_active Withdrawn
- 2003-09-12 JP JP2004568905A patent/JP2006506443A/ja not_active Withdrawn
- 2003-09-12 WO PCT/IB2003/004005 patent/WO2004026865A1/en not_active Ceased
- 2003-09-12 AP AP2005003262A patent/AP2005003262A0/xx unknown
- 2003-09-12 EA EA200500286A patent/EA200500286A1/ru unknown
- 2003-09-12 PL PL03375973A patent/PL375973A1/xx not_active Application Discontinuation
- 2003-09-12 OA OA1200500074A patent/OA12925A/en unknown
- 2003-09-12 KR KR1020057004662A patent/KR20050057441A/ko not_active Ceased
- 2003-09-12 BR BR0314286-8A patent/BR0314286A/pt not_active IP Right Cessation
- 2003-09-15 TW TW092125380A patent/TW200410954A/zh unknown
- 2003-09-16 UY UY27983A patent/UY27983A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103359A patent/AR041275A1/es unknown
- 2003-09-17 PE PE2003000951A patent/PE20050076A1/es not_active Application Discontinuation
- 2003-09-17 PA PA20038583101A patent/PA8583101A1/es unknown
- 2003-09-17 US US10/667,167 patent/US7030125B2/en not_active Expired - Fee Related
-
2005
- 2005-02-14 IS IS7695A patent/IS7695A/is unknown
- 2005-03-17 EC EC2005005685A patent/ECSP055685A/es unknown
- 2005-03-18 CO CO05025189A patent/CO5550458A2/es not_active Application Discontinuation
- 2005-03-18 MA MA28158A patent/MA27444A1/fr unknown
- 2005-04-15 NO NO20051852A patent/NO20051852L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0314286A (pt) | 2005-08-02 |
| ECSP055685A (es) | 2005-05-30 |
| NO20051852L (no) | 2005-06-16 |
| CA2499332A1 (en) | 2004-04-01 |
| AP2005003262A0 (en) | 2005-03-31 |
| TW200410954A (en) | 2004-07-01 |
| UY27983A1 (es) | 2004-04-30 |
| IS7695A (is) | 2005-02-14 |
| AU2003263431A1 (en) | 2004-04-08 |
| KR20050057441A (ko) | 2005-06-16 |
| HRP20050246A2 (en) | 2005-10-31 |
| WO2004026865A1 (en) | 2004-04-01 |
| US7030125B2 (en) | 2006-04-18 |
| MXPA05002378A (es) | 2005-05-23 |
| OA12925A (en) | 2006-10-13 |
| PA8583101A1 (es) | 2004-04-23 |
| US20040116473A1 (en) | 2004-06-17 |
| PL375973A1 (en) | 2005-12-12 |
| EP1542995A1 (en) | 2005-06-22 |
| EA200500286A1 (ru) | 2005-08-25 |
| PE20050076A1 (es) | 2005-03-26 |
| MA27444A1 (fr) | 2005-07-01 |
| JP2006506443A (ja) | 2006-02-23 |
| CO5550458A2 (es) | 2005-08-31 |
| CN1681809A (zh) | 2005-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041275A1 (es) | Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica | |
| AR041273A1 (es) | Compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
| AR041272A1 (es) | Compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) y composicion farmaceutica que los contiene | |
| AR041274A1 (es) | Compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
| AR041276A1 (es) | Compuestos de triazol como inhibidores del factor crecimiento transformador (tgf) | |
| CN114159430B (zh) | 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物 | |
| AR043449A1 (es) | Compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf) | |
| TWI759301B (zh) | 聚乙二醇化卡非佐米化合物 | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| AR039660A1 (es) | Inhibidores de aril-heteroariloxi-ariloxi-pirimidin-2,4,6-triona metaloproteinasa | |
| HU229510B1 (en) | Pleuromutilin derivatives having antibacterial activity | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos | |
| PA8573501A1 (es) | Derivados de benzoxazina y su empleo | |
| RU2008118422A (ru) | Производные 5-хинолина, обладающие антибактериальной активностью | |
| BRPI0417844A (pt) | derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina | |
| NO892295D0 (no) | Fremgangsmaate for fremstilling av nye cefemforbindelser. | |
| JP2007508301A5 (enExample) | ||
| KR910006309A (ko) | 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제 | |
| PE20241186A1 (es) | Compuestos de cd73 | |
| CA2665347C (en) | Process for the preparation of pleuromutilins | |
| US20180297966A1 (en) | Compounds, compositions, and methods of making and using the same | |
| US11840495B2 (en) | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds | |
| US20250019365A1 (en) | Compositions and methods for preserving and/or restoring neural function | |
| US20240208935A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
| EP4486738A1 (en) | Small molecule inhibitors of enpp1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |